Your browser is no longer supported. Please, upgrade your browser.
Settings
ASND Ascendis Pharma A/S daily Stock Chart
ASND [NASD]
Ascendis Pharma A/S
Index- P/E- EPS (ttm)-4.15 Insider Own22.43% Shs Outstand47.10M Perf Week-3.31%
Market Cap5.17B Forward P/E- EPS next Y-4.92 Insider Trans0.00% Shs Float6.00M Perf Month-4.03%
Income-186.70M PEG- EPS next Q-1.21 Inst Own39.41% Short Float40.23% Perf Quarter-1.75%
Sales23.50M P/S220.05 EPS this Y14.10% Inst Trans3.63% Short Ratio10.45 Perf Half Y-11.08%
Book/sh15.29 P/B7.18 EPS next Y-17.60% ROA-26.30% Target Price156.26 Perf Year69.77%
Cash/sh15.39 P/C7.13 EPS next 5Y24.00% ROE-29.10% 52W Range54.66 - 133.96 Perf YTD75.24%
Dividend- P/FCF- EPS past 5Y- ROI-55.10% 52W High-18.04% Beta0.62
Dividend %- Quick Ratio15.70 Sales past 5Y-12.30% Gross Margin- 52W Low100.84% ATR5.01
Employees216 Current Ratio15.70 Sales Q/Q11115.00% Oper. Margin- RSI (14)48.80 Volatility5.31% 4.66%
OptionableYes Debt/Eq0.06 EPS Q/Q34.90% Profit Margin- Rel Volume1.69 Prev Close116.24
ShortableYes LT Debt/Eq0.05 EarningsNov 18 AMC Payout- Avg Volume230.96K Price109.79
Recom1.50 SMA20-3.41% SMA503.57% SMA200-2.57% Volume389,521 Change-5.55%
Oct-11-19Initiated Morgan Stanley Overweight $128
Mar-25-19Initiated Evercore ISI Outperform
Jan-24-19Upgrade Leerink Partners Mkt Perform → Outperform
Jan-24-19Initiated Cantor Fitzgerald Overweight $102
Jun-26-18Initiated Stifel Buy $85
Apr-02-18Reiterated Leerink Partners Mkt Perform $37 → $64
May-11-17Initiated JP Morgan Overweight $36
Mar-09-17Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17Initiated Credit Suisse Outperform $28
Sep-26-16Initiated Wedbush Outperform $34
Dec-04-19 12:42PM  Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND) Insider Monkey
Nov-23-19 11:34PM  Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-22-19 05:38AM  Ascendis Pharma A/S Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Nov-21-19 09:05AM  Top Ranked Momentum Stocks to Buy for November 21st Zacks
Nov-18-19 04:01PM  Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results GlobeNewswire
10:33AM  Top Ranked Momentum Stocks to Buy for November 18th Zacks
01:02AM  New Records and New Milestones Zacks
Nov-14-19 04:01PM  Ascendis Pharma Expands TransCon PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States GlobeNewswire
Nov-12-19 09:52AM  What's in Store for Helmerich & Payne (HP) in Q4 Earnings? Zacks
Nov-11-19 07:50AM  5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
Nov-08-19 04:02PM  Ascendis Pharma A/S Announces Upcoming Investor Presentation in November GlobeNewswire
Nov-06-19 04:02PM  Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon Technology in Oncology at SITC 2019 GlobeNewswire
Nov-05-19 11:50AM  CannTrust (CTST) to Report Q3 Earnings: What's in Store? Zacks
11:13AM  Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-04-19 06:30PM  Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18 GlobeNewswire
Oct-29-19 09:00AM  Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why Zacks
Oct-24-19 11:47AM  How to invest in biotech stocks like a Nobel Prize winner MarketWatch
Oct-21-19 04:04PM  Ascendis Pharma A/S Receives Orphan Designation for TransCon hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe GlobeNewswire
Oct-14-19 08:44PM  Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND) Insider Monkey
Oct-01-19 03:50PM  Edited Transcript of ASND earnings conference call or presentation 28-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-26-19 08:25AM  Ascendis Pharma A/S Announces Upcoming Investor Presentation in October GlobeNewswire -6.52%
Sep-19-19 08:30AM  When Will Ascendis Pharma A/S (NASDAQ:ASND) Run Out Of Money? Simply Wall St.
Sep-12-19 04:20PM  Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon CNP at International Skeletal Dysplasia Society Meeting GlobeNewswire
Sep-03-19 03:20AM  3 Biopharma Stocks With Over 50% Upside TipRanks
Aug-29-19 05:15PM  Ascendis Pharma A/S Announces Three Investor Presentations in September GlobeNewswire
04:23AM  Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript Motley Fool
Aug-28-19 04:01PM  Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-14-19 05:30PM  Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28 GlobeNewswire
Jul-18-19 04:12PM  Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon CNP in Children with Achondroplasia GlobeNewswire
Jun-19-19 08:30AM  Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs GlobeNewswire
Jun-10-19 10:10AM  Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND) Insider Monkey
May-31-19 02:02AM  Edited Transcript of ASND earnings conference call or presentation 30-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-30-19 04:02PM  Ascendis Pharma A/S Reports First Quarter 2019 Financial Results GlobeNewswire
02:30PM  Ascendis Pharma A/S to Host Earnings Call ACCESSWIRE
May-20-19 07:30AM  Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone GlobeNewswire
May-16-19 08:00AM  Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30 GlobeNewswire
May-07-19 04:02PM  Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference GlobeNewswire
12:43PM  Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap Insider Monkey
May-06-19 11:09AM  What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health Simply Wall St.
Apr-29-19 09:28AM  Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ? Insider Monkey
Apr-27-19 08:40AM  Glenview Capital Managements Stock Pitches At 2018 Sohn Conference Insider Monkey
Apr-24-19 05:26PM  Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences GlobeNewswire
Apr-23-19 08:59AM  Joseph Jolsons Harvest Capital Strategies Return, AUM, and Holdings Insider Monkey
Apr-20-19 12:25PM  Best Stock Pick From The 2018 Sohn Conference (Part II) Insider Monkey
Apr-15-19 01:21PM  Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-11-19 01:11AM  What Happened With Light Streets Glen Kachers Best Idea at 2018 Sohn Conference? Insider Monkey
Apr-08-19 01:06PM  Mangrove Partners Nathaniel Augusts Best Idea At 2018 Sohn Conference Insider Monkey
Apr-07-19 11:59PM  Sarissa Capital Management Hires New President Insider Monkey
Apr-04-19 01:14AM  Ascendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call Transcript Motley Fool
Apr-03-19 04:01PM  Ascendis Pharma A/S Reports Full Year 2018 Financial Results GlobeNewswire
02:30PM  Ascendis Pharma A/S Sponsored ADR to Host Earnings Call ACCESSWIRE
Mar-27-19 05:00PM  Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3 GlobeNewswire
Mar-25-19 02:45PM  Ascendis Pivotal Growth Hormone Deficiency Study Data Positive Zacks
02:00PM  Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life GlobeNewswire
Mar-24-19 12:45PM  Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone GlobeNewswire
Mar-14-19 01:08PM  ValueAct Capitals CBRE Recommendation Delivers 150% Gain Insider Monkey
Mar-12-19 10:56AM  What Makes Ascendis Pharma A/S (ASND) a New Buy Stock Zacks
Mar-07-19 07:10AM  Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-06-19 02:31PM  Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602% Simply Wall St. -8.53%
10:00AM  Under the Radar Cannabis Stock-THC Therapeutics, Inc. ACCESSWIRE
04:05AM  Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS Benzinga
Mar-05-19 08:07PM  Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs GlobeNewswire
09:43AM  Company News For Mar 5, 2019 Zacks
Mar-04-19 04:01PM  Ascendis Pharma A/S Announces Proposed Public Offering of ADSs GlobeNewswire +74.00%
06:30AM  Ascendis Pharma Announces Once-weekly TransCon Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency GlobeNewswire
Feb-28-19 08:20PM  Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia GlobeNewswire
07:45AM  Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-13-19 09:53AM  Ascendis Pharma Files IND for Hypoparathyroidism Candidate Zacks
Feb-11-19 05:27PM  Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism GlobeNewswire
Jan-25-19 09:18AM  All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy Zacks
Jan-17-19 12:29PM  Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-07-19 09:00AM  Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches GlobeNewswire
Dec-21-18 04:01PM  Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -7.58%
Dec-12-18 02:57AM  Should You Buy Ascendis Pharma A/S (ASND)? Insider Monkey
Nov-28-18 11:03PM  Ascendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results GlobeNewswire
04:01PM  Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP GlobeNewswire
Nov-14-18 04:15PM  Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28 GlobeNewswire -8.08%
Nov-08-18 04:48PM  Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon Endocrinology Rare Disease Therapies in China GlobeNewswire
Nov-02-18 09:00AM  Ascendis Pharma A/S Announces Upcoming Investor Presentations GlobeNewswire
Oct-26-18 08:35AM  Market Trends Toward New Normal in Ascendis Pharma A/S, Diodes, Laureate Education, Randgold Resources, Fastenal, and LTC Properties Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-01-18 08:00AM  Today's Research Reports on Trending Tickers: Aurora Cannabis and Ascendis Pharma ACCESSWIRE
Sep-27-18 07:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Ascendis Pharma A/S, Fluor, InterDigital, Ruth's Hospitality Group, Aramark, and ManTech International New Research Emphasizes Economic Growth GlobeNewswire
06:57AM  Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-17-18 04:10PM  Ascendis Pharma A/S Announces Support for Childrens Growth Awareness Week and Day 2018 GlobeNewswire
Sep-06-18 04:02PM  Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences GlobeNewswire
Aug-31-18 04:01PM  Ascendis Pharma A/S Announces Upcoming Investor Presentations GlobeNewswire
11:48AM  Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript Motley Fool
Aug-29-18 04:01PM  Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Ascendis Pharma A/S Sponsored ADR to Host Earnings Call ACCESSWIRE
Aug-15-18 04:15PM  Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29 GlobeNewswire
Aug-02-18 07:00AM  Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-23-18 04:44PM  Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting GlobeNewswire
Jun-06-18 05:35PM  Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism GlobeNewswire
08:15AM  Investor Expectations to Drive Momentum within Gladstone Commercial, Old Line Bancshares, Randgold Resources, Turning Point Brands, Capella Education, and Ascendis Pharma A/S Discovering Underlying Factors of Influence GlobeNewswire
Jun-04-18 10:03PM  Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-30-18 04:02PM  Ascendis Pharma A/S Reports First Quarter 2018 Financial Results GlobeNewswire
May-16-18 04:20PM  Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30 GlobeNewswire
May-10-18 07:25AM  Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP ACCESSWIRE
May-08-18 07:00AM  Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP GlobeNewswire
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. The company was founded in 2006 and is headquartered in Hellerup, Denmark.